Skip to Content
Merck
CN

20034

Supelco

ORBO™ 403 Tenax® TA specially treated (60/80), 100/50 mg

W,W,W separators, O.D. × L 6 mm × 105 mm, pkg of 50 ea

Synonym(s):

ORBO™ Tenax® TA

Sign Into View Organizational & Contract Pricing

Select a Size

About This Item

UNSPSC Code:
47131900

Key Documents

View All Documentation
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

material

W,W,W separators

Agency

NIOSH 2510

product line

ORBO™

composition

Bed A, 100 mg
Bed B, 50 mg

packaging

pkg of 50 ea

manufacturer/tradename

ORBO™ 403

technique(s)

active air sampling: suitable

O.D. × L

6 mm × 105 mm

matrix

Tenax TA (specially treated)

particle size

60-80 mesh

application(s)

air monitoring
environmental
industrial hygiene

Looking for similar products? Visit Product Comparison Guide

Legal Information

ORBO is a trademark of Sigma-Aldrich Co. LLC
Tenax is a registered trademark of Buchem B.V.

Pictograms

Exclamation mark
GHS07

Signal Word

Warning

Hazard Statements

H315,H319,H335

Hazard Classifications

Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3

Target Organs

Respiratory system

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documents section.

If you need assistance, please contact Customer Support

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

K Flo et al.
Scandinavian journal of clinical and laboratory investigation, 55(8), 715-721 (1995-12-01)
Elevated extracellular cGMP levels have been observed in various clinical conditions, and the analyte has been proposed as a diagnostic marker of cardiovascular as well as malignant diseases. However, the use of extracellular cGMP as a pathophysiological marker requires detailed
Bjørn T Moe et al.
Anticancer research, 29(4), 1047-1052 (2009-05-06)
Endometrial hyperplasia is a precursor lesion of endometrial carcinoma. Clinical studies of endometrial hyperplasia have shown that levonorgestrel (LNG) is more therapeutically effective than medroxyprogesterone acetate (MPA). The present pharmacological in vitro study was performed to compare progestin effects on
A Orbo et al.
Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke, 117(7), 972-976 (1997-03-10)
The development of female steroid hormone-related neoplasms such as gynaecologic and mammary cancers is influenced by hormones administered exogenously. Hormonal contraceptives and hormone replacement therapy both affect the risk of developing cancers in the endometrium, cervix, ovarium, and mammary glands.
[Explorative abrasion--obsolete?].
A Orbo
Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke, 111(19), 2397-2398 (1991-08-20)
Anne Ørbo et al.
British journal of cancer, 115(6), 725-730 (2016-08-19)
The aim of the present study was to investigate whether changes in the tissue expression of human epididymis-specific protein 4 (HE4) could predict therapy resistance and relapse after progestin hormone therapy for medium- and low-risk endometrial hyperplasia. Endometrial biopsies were
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service